Submitted:
02 May 2024
Posted:
06 May 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Participants
2.2. Procedures
2.3. Measures
2.4. Statistical Analyses
3. Results
3.1. Sample Characteristics
3.2. Sense of Presence and Emotions
3.3. Sense of Presence and Clinical Outcomes
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- McCutcheon RA, Reis Marques T, Howes OD. Schizophrenia—An Overview. JAMA Psychiatry. 2020, 77, 201–210. [CrossRef] [PubMed]
- Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG; et al. Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016. Schizophr Bull. 2018, 44, 1195–1203. [CrossRef] [PubMed]
- Canadian Chronic Disease Surveillance System (CCDSS) [Internet]. 2023 [cited 2024-02-13]. Available from: https://health-infobase.canada.ca/ccdss/data-tool/Index.
- Jin H, Mosweu I. The Societal Cost of Schizophrenia: A Systematic Review. PharmacoEconomics. 2017, 35, 25–42. [CrossRef] [PubMed]
- Chaix J, Ma E, Nguyen A, Ortiz Collado MA, Rexhaj S, Favrod J. Safety-seeking behaviours and verbal auditory hallucinations in schizophrenia. Psychiatry Research. 2014, 220, 158–162. [CrossRef] [PubMed]
- Moseley P, Fernyhough C, Ellison A. Auditory verbal hallucinations as atypical inner speech monitoring, and the potential of neurostimulation as a treatment option. Neurosci Biobehav Rev. 2013;37(10 Pt 2):2794-805. [CrossRef]
- Kråkvik B, Larøi F, Kalhovde AM, Hugdahl K, Kompus K, Salvesen Ø; et al. Prevalence of auditory verbal hallucinations in a general population: A group comparison study. Scand J Psychol. 2015, 56, 508–515. [CrossRef] [PubMed]
- Brederoo SG, de Boer JN, Linszen MMJ, Blom RE, Begemann MJH, Sommer IEC. Social Deafferentation and the Relation Between Loneliness and Hallucinations. Schizophrenia Bulletin. 2023;49(Supplement_1):S25-S32. [CrossRef]
- Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: A review. British Medical Bulletin. 2015, 114, 169–179. [CrossRef] [PubMed]
- Pandey A, Kalita KN. Treatment-resistant schizophrenia: How far have we traveled? Front Psychiatry. 2022, 13, 994425. [CrossRef] [PubMed]
- Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. JAMA Psychiatry. 2017, 74, 675–684. [CrossRef]
- Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA; et al. The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements. Schizophrenia Bulletin. 2009, 36, 71–93. [CrossRef]
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF; et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The World Journal of Biological Psychiatry. 2012, 13, 318–378. [CrossRef]
- Siskind D, Siskind V, Kisely S. Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis. The Canadian Journal of Psychiatry. 2017, 62, 772–777. [CrossRef] [PubMed]
- Morrison AP, Law H, Carter L, Sellers R, Emsley R, Pyle M; et al. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: A randomised controlled pilot and feasibility study. Lancet Psychiatry. 2018, 5, 411–423. [CrossRef] [PubMed]
- Bighelli I, Huhn M, Schneider-Thoma J, Krause M, Reitmeir C, Wallis S; et al. Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: A systematic review and single-group meta-analysis. BMC Psychiatry. 2018, 18, 380. [CrossRef] [PubMed]
- Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive–behavioural therapy for the symptoms of schizophrenia: Systematic review and meta-analysis with examination of potential bias. British Journal of Psychiatry. 2014, 204, 20–29. [CrossRef] [PubMed]
- Wiebe A, Kannen K, Selaskowski B, Mehren A, Thöne A-K, Pramme L; et al. Virtual reality in the diagnostic and therapy for mental disorders: A systematic review. Clinical Psychology Review. 2022, 98, 102213. [CrossRef] [PubMed]
- Geraets CNW, Snippe E, van Beilen M, Pot-Kolder RMCA, Wichers M, van der Gaag M; et al. Virtual reality based cognitive behavioral therapy for paranoia: Effects on mental states and the dynamics among them. Schizophrenia Research. 2020, 222, 227–234. [CrossRef]
- Pot-Kolder RMCA, Geraets CNW, Veling W, van Beilen M, Staring ABP, Gijsman HJ; et al. Virtual-reality-based cognitive behavioural therapy versus waiting list control for paranoid ideation and social avoidance in patients with psychotic disorders: A single-blind randomised controlled trial. The Lancet Psychiatry. 2018, 5, 217–226. [CrossRef]
- Dellazizzo L, Potvin S, Phraxayavong K, Dumais A. One-year randomized trial comparing virtual reality-assisted therapy to cognitive-behavioral therapy for patients with treatment-resistant schizophrenia. NPJ Schizophr. 2021, 7, 9. [CrossRef]
- du Sert OP, Potvin S, Lipp O, Dellazizzo L, Laurelli M, Breton R; et al. Virtual reality therapy for refractory auditory verbal hallucinations in schizophrenia: A pilot clinical trial. Schizophr Res. 2018, 197, 176–181. [CrossRef]
- Craig TK, Rus-Calafell M, Ward T, Leff JP, Huckvale M, Howarth E; et al. AVATAR therapy for auditory verbal hallucinations in people with psychosis: A single-blind, randomised controlled trial. Lancet Psychiatry. 2018, 5, 31–40. [CrossRef]
- McCreery MP, Schrader PG, Krach SK, Boone R. A sense of self: The role of presence in virtual environments. Computers in Human Behavior. 2013, 29, 1635–1640. [CrossRef]
- Slater, M. How Colorful Was Your Day? Why Questionnaires Cannot Assess Presence in Virtual Environments. Presence. 2004, 13, 484–493. [Google Scholar] [CrossRef]
- Nowak K, Biocca F. The Effect of the Agency and Anthropomorphism on Users' Sense of Telepresence, Copresence, and Social Presence in Virtual Environments. Presence Teleoperators & Virtual Environments. 2003, 12, 481–494. [CrossRef]
- Ochs C, Sonderegger A. The Interplay Between Presence and Learning. Frontiers in Virtual Reality. 2022;3. [CrossRef]
- Giuseppe R, Fabrizia M. Being There: Understanding the Feeling of Presence in a Synthetic Environment and its Potential for Clinical Change. In: Christiane E, editor. Virtual Reality in Psychological, Medical and Pedagogical Applications. Rijeka: IntechOpen; 2012. p. Ch. 1.
- Abargil M, Tishby O. How therapists' emotion recognition relates to therapy process and outcome. Clin Psychol Psychother. 2022, 29, 1001–1019. [CrossRef] [PubMed]
- Asano, K. Emotion Processing and the Role of Compassion in Psychotherapy from the Perspective of Multiple Selves and the Compassionate Self. Case Rep Psychiatry. 2019, 2019, 7214752. [Google Scholar] [CrossRef] [PubMed]
- Hudon A, Lammatteo V, Rodrigues-Coutlée S, Dellazizzo L, Giguère S, Phraxayavong K; et al. Exploration of the role of emotional expression of treatment-resistant schizophrenia patients having followed virtual reality therapy: A content analysis. BMC Psychiatry. 2023, 23, 420. [CrossRef] [PubMed]
- Malbos E, Rapee RM, Kavakli M. A controlled study of agoraphobia and the independent effect of virtual reality exposure therapy. Australian & New Zealand Journal of Psychiatry. 2013, 47, 160–168. [CrossRef] [PubMed]
- Villani D, Riva F, Riva G. New Technologies for Relaxation: The Role of Presence. International Journal of Stress Management Copyright. 2007, 14, 260–274. [CrossRef]
- Rus-Calafell M, Ward T, Zhang XC, Edwards CJ, Garety P, Craig T. The Role of Sense of Voice Presence and Anxiety Reduction in AVATAR Therapy. J Clin Med. 2020;9(9). [CrossRef]
- Faragher EB, Haddock G, McCarron J, Tarrier N. Scales to measure dimensions of hallucinations and delusions: The psychotic symptom rating scales (PSYRATS). Psychological Medicine. 1999, 29, 879–889. [CrossRef]
- Woodward TS, Jung K, Hwang H, Yin J, Taylor L, Menon M; et al. Symptom dimensions of the psychotic symptom rating scales in psychosis: A multisite study. Schizophr Bull. 2014;40 Suppl 4(Suppl 4):S265-74. [CrossRef]
- Schubert T, Friedmann F, Regenbrecht H. The Experience of Presence: Factor Analytic Insights. Presence. 2001, 10, 266–281. [CrossRef]
- Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth. 2019, 22, 67–72. [CrossRef]
- Oliver, D. Howes, M. R.C.Psych., Ph.D.,, Rob McCutcheon, M.R.C.Psych.,, Ofer Agid, M.D.,, Andrea de Bartolomeis, M.D., Ph.D.,, Nico J.M. van Beveren, M.D., Ph.D.,, Michael L. Birnbaum, M.D.,; et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. American Journal of Psychiatry. 2017, 174, 216–229. [Google Scholar] [CrossRef] [PubMed]
- Zhang L, Bai A, Tang Z, Liu X, Li Y, Ma J. Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: A real-world study. Frontiers in Psychiatry. 2023;14. [CrossRef]
- Loebel A, Citrome L, Correll CU, Xu J, Cucchiaro J, Kane JM. Treatment of early non-response in patients with schizophrenia: Assessing the efficacy of antipsychotic dose escalation. BMC Psychiatry. 2015, 15, 271. [CrossRef]
- The Mann - Whitney U: A Test for Assessing Whether Two Independent Samples Come from the Same Distribution2007.
- Lakens, D. Calculating and reporting effect sizes to facilitate cumulative science: A practical primer for t-tests and ANOVAs. Frontiers in Psychology. 2013;4. [CrossRef]
- IBM Corp. Released 2021. IBM SPSS Statistics for Windows VA, NY: IBM Corp.
- Akoglu, H. User's guide to correlation coefficients. Turkish Journal of Emergency Medicine. 2018, 18, 91–93. [Google Scholar] [CrossRef]
- Sullivan GM, Feinn R. Using Effect Size-or Why the P Value Is Not Enough. J Grad Med Educ. 2012, 4, 279–282. [CrossRef] [PubMed]
- Spidel A, Lecomte T, Kealy D, Daigneault I. Acceptance and commitment therapy for psychosis and trauma: Improvement in psychiatric symptoms, emotion regulation, and treatment compliance following a brief group intervention. Psychology and Psychotherapy: Theory, Research and Practice. 2018, 91, 248–261. [CrossRef]
- Riches S, Elghany S, Garety P, Rus-Calafell M, Valmaggia L. Factors Affecting Sense of Presence in a Virtual Reality Social Environment: A Qualitative Study. Cyberpsychol Behav Soc Netw. 2019, 22, 288–292. [CrossRef]
- Diemer J, Alpers GW, Peperkorn HM, Shiban Y, Mühlberger A. The impact of perception and presence on emotional reactions: A review of research in virtual reality. Frontiers in Psychology. 2015;6. [CrossRef]
- Beaudoin M, Potvin S, Machalani A, Dellazizzo L, Bourguignon L, Phraxayavong K; et al. The therapeutic processes of avatar therapy: A content analysis of the dialogue between treatment-resistant patients with schizophrenia and their avatar. Clinical Psychology & Psychotherapy. 2021, 28, 500–518. [CrossRef] [PubMed]
- Freeman J, Lessiter J, Pugh K, Keogh E. When Presence and emotion are related, and when they are not. 2005.
- Price M, Anderson P. The role of presence in virtual reality exposure therapy. J Anxiety Disord. 2007, 21, 742–751. [CrossRef]

| Characteristics | Mean or N | SD or % |
|---|---|---|
| Age, years | 41.9 | 12.9 |
| Male sex | 84 | 68.3 |
| Ethnicity | ||
| Caucasian | 96 | 78.0 |
| African American | 9 | 8.1 |
| Latin American | 3 | 2.4 |
| Other | 14 | 11.4 |
| Highest educational attainment |
||
| Less than high school | 38 | 30.9 |
| High school diploma | 23 | 18.7 |
| Postsecondary education | 62 | 50.4 |
| Diagnosis | ||
| Schizophrenia | 97 | 78.9 |
| Schizoaffective disorder | 26 | 21.1 |
| GRS mean scores | IPQ mean scores | |||||
|---|---|---|---|---|---|---|
| N | rs | p-value | N | rs | p-value | |
| Mean emotional response | ||||||
| Sadness | 68 | -0.033 | 0.790 | 67 | 0.093 | 0.452 |
| Anger | 112 | -0.151 | 0.112 | 84 | 0.085 | 0.442 |
| Anxiety | 112 | -0.092 | 0.333 | 84 | 0.039 | 0.725 |
| Fear | 112 | -0.173 | 0.067 | 84 | 0.113 | 0.306 |
| Serenity | 112 | 0.242* | 0.010 | 84 | 0.113 | 0.305 |
| Control | 112 | 0.337** | <0,001 | 84 | 0.225* | 0.040 |
| Maximal emotional intensity | ||||||
| Positive | 112 | 0.355** | <0,001 | 84 | 0.209 | 0.056 |
| Negative | 112 | -0.153 | 0.107 | 84 | 0.097 | 0.381 |
| Total | 112 | 0.398** | <0,001 | 84 | 0.284** | 0.009 |
| Variation in the severity of auditory hallucinations (3-month follow-up vs. baseline) | ||||||
| PSYRATS—AH (%) | 60 | -0.384** | 0.002 | 33 | -0.257 | 0.149 |
| N | Responders Mean score (SD) |
Non-responders Mean score (SD) |
p-value | Cohen’s d | |
|---|---|---|---|---|---|
| GRS | 60 | 8.9 (3.5) | 7.4 (1.4) | 0.047 | 0.543 |
| IPQ | 33 | 42.1 (7.0) | 41.8 (9.3) | 0.963 | 0.034 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).